相关实验视频

Updated: Jan 12, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

在多发性骨髓瘤中识别和转化免疫治疗的新型点

Yijie Wang¹, Yonghuan Wang¹, Jingyuan Ma¹

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

Chinese medical journal

|November 1, 2025

概括

多发性骨髓瘤免疫疗法显示出希望,但复发患者仍然面临挑战. 需要新的策略来克服耐药性并提高治疗疗效.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

多发性骨髓瘤 (MM) 是一种由染色体不稳定性和复发性标志着的血细胞恶性瘤.
了解免疫失调的进展刺激了对MM的免疫疗法的开发.
现有的免疫疗法已经证明有效,特别是在复发/耐药病例中.

研究的目的:

对多发性骨髓瘤的免疫疗法进行审查.
为了突出治疗严重预先治疗的患者的挑战.
强调需要新的治疗目标和策略.

主要方法:

对评估各种免疫治疗策略的临床试验的审查.
对MM进展中的免疫失调和抑制的分析.
讨论包括耐药性和免疫逃脱在内的挑战.

主要成果:

免疫调节性伊米德药物,单克隆抗体和细胞疗法已经证明了临床疗效.
取得了重大进展,特别是在复发性和耐火性多发性髓瘤方面.
尽管有进展,但严重预治疗的患者仍然面临着有限的选择和抵抗.

结论:

免疫疗法改变了多发性骨髓瘤的治疗方法,为复发患者提供了希望.
克服耐药性和免疫逃脱仍然是改善结果的关键.
进一步研究新的点和组合疗法对于推进MM护理至关重要.

关键词:

抗体药物联结物抗体药物联结物 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 化学抗原受体T细胞治疗免疫调节性胺基类药物是免疫调节剂.免疫治疗是一种免疫疗法.多发性骨髓瘤是一种多发性骨髓瘤.

更多相关视频

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...